This article is distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
WHO Classification of tumours of the central nervous system. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. Lyon: IARC Press; 2007.WHO Classification of tumours of the central nervous systemLouisDNOhgakiHWiestlerODCaveneeWKLyonIARC Press2007Search in Google Scholar
CBTRUS, Central Brain Tumor Registry of the United States. 2007–2008. Primary brain tumors in the United States. Statistical report. 2000– 2004 years of data collected. Available from: http://www.cbtrus.org/ reports/2007-2008/2007report.pdf. Accessed on 10 November 2013.CBTRUS, Central Brain Tumor Registry of the United States2007–2008. Primary brain tumors in the United States. Statistical report. 2000– 2004 years of data collectedAvailable fromhttp://www.cbtrus.org/ reports/2007-2008/2007report.pdfAccessed on 10 November2013Search in Google Scholar
Kase M, Minajeva A, Niinepuu K, Kase S, Vardja M, Asser T, et al. Impact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiforme. Radiol Oncol 2013; 47: 405-10.KaseMMinajevaANiinepuuKKaseSVardjaMAsserTet alImpact of CD133 positive stem cell proportion on survival in patients with glioblastoma multiformeRadiol Oncol2013474051010.2478/raon-2013-0055Search in Google Scholar
Fisher JL, Schwartzbaum JA, Wrensch M, Wiemels JL. Epidemiology of brain tumors. Neurol Clin 2007; 25: 867-90.FisherJLSchwartzbaumJAWrenschMWiemelsJLEpidemiology of brain tumorsNeurol Clin2007258679010.1016/B978-1-4160-5316-3.00108-8Search in Google Scholar
Smrdel U, Kovac V, Popovic M, Zwitter M. Glioblastoma patients in Slovenia from 1997 to 2008. Radiol Oncol 2014; 48: 72-9.SmrdelUKovacVPopovicMZwitterMGlioblastoma patients in Slovenia from 1997 to 2008Radiol Oncol20144872910.2478/raon-2014-0002Search in Google Scholar
Zakelj MP, Zadnik V, Zagar T, Zakotnik B. Survival of cancer patients, diagnosed in 1991-2005 in Slovenia. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia; 2009. p. 229.ZakeljMPZadnikVZagarTZakotnikBSurvival of cancer patients diagnosed in 1991-2005 in SloveniaLjubljanaInstitute of Oncology Ljubljana Epidemiology and Cancer Registry Cancer Registry of Republic of Slovenia2009229Search in Google Scholar
Linos E, Raine T, Alonso A, Michaud D. Atopy and risk of brain tumours: a metaanalysis. J Natl Cancer Inst 2007; 99: 1544-50.LinosERaineTAlonsoAMichaudDAtopy and risk of brain tumours: a metaanalysisJ Natl Cancer Inst20079915445010.1093/jnci/djm170Search in Google Scholar
Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, et al. Serum IgE, tumour epidermal growth factor receptor expression and inherited polymorphisms associated with gliomas survival. Cancer Res 2006; 66: 4531-41.WrenschMWienckeJKWiemelsJMiikeRPatokaJMoghadassiMet alSerum IgE tumour epidermal growth factor receptor expression and inherited polymorphisms associated with gliomas survivalCancer Res20066645314110.1158/0008-5472.CAN-05-4032Search in Google Scholar
Farell CJ, Plotkin SR. Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau and other syndromes. Neurol Clin 2007; 25: 925-46.FarellCJPlotkinSRGenetic causes of brain tumors: neurofibromatosis, tuberous sclerosis von Hippel-Lindau and other syndromesNeurol Clin2007259254610.1016/j.ncl.2007.07.008Search in Google Scholar
Schwartzbaum JA, Fisher JL, Kenneth DA, Wrensch M. Epidemiology and molecular pathology of gliomas. Nature 2006; 2: 494-503.SchwartzbaumJAFisherJLKennethDAWrenschMEpidemiology and molecular pathology of gliomasNature2006249450310.1038/ncpneuro0289Search in Google Scholar
Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.GalliRBindaEOrfanelliUCipellettiBGrittiADe VitisSet alIsolation and characterization of tumorigenic stem-like neural precursors from human glioblastomaCancer Res20046470112110.1158/0008-5472.CAN-04-1364Search in Google Scholar
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumor initiating cells. Nature 2004; 432: 396-401.SinghSKHawkinsCClarkeIDSquireJABayaniJHideTet alIdentification of human brain tumor initiating cellsNature200443239640110.1038/nature03128Search in Google Scholar
Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2A (p16) or RB alterations occur in majority of glioblastomas and are inversely correlated. Cancer Res 1996; 56: 150-3.UekiKOnoYHensonJWEfirdJTvon DeimlingALouisDNCDKN2A (p16) or RB alterations occur in majority of glioblastomas and are inversely correlatedCancer Res1996561503Search in Google Scholar
Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H. Acquisition of the glioblatoma phenotype during astrocytoma progression is associated with loss of heterozygocity on 10q25-qter. Am J Pathol 1999; 155: 387-94.FujisawaHKurrerMReisRMYonekawaYKleihuesPOhgakiHAcquisition of the glioblatoma phenotype during astrocytoma progression is associated with loss of heterozygocity on 10q25-qterAm J Pathol19991553879410.1016/S0002-9440(10)65135-8Search in Google Scholar
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275: 1943-7.LiJYenCLiawDPodsypaninaKBoseSWangSIet alPTEN, a putative protein tyrosine phosphatase gene mutated in human brain breast, and prostate cancerScience19972751943710.1126/science.275.5308.1943Search in Google Scholar
Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGFR receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-23.WatanabeKTachibanaOSataKYonekawaYKleihuesPOhgakiHOverexpression of the EGFR receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomasBrain Pathol199662172310.1111/j.1750-3639.1996.tb00848.xSearch in Google Scholar
Kleihues P, Ohgaki H. Primary and secondary globlastomas: from concept to clinical diagnosis. Neuro Oncol 1999; 1: 44-51.KleihuesPOhgakiHPrimary and secondary globlastomas: from concept to clinical diagnosisNeuro Oncol19991445110.1093/neuonc/1.1.44Search in Google Scholar
Devaux BC, O’Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy and outcome. J Neurosurg 1993; 78: 767-75.DevauxBCO’FallonJRKellyPJResection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters therapy and outcomeJ Neurosurg1993787677510.3171/jns.1993.78.5.0767Search in Google Scholar
Laws ER, Parney IF, Huang W, Anderson F, Morris AM, Asher A, et al. Survival following surgery and prognostic factors for recently diagnosed malignant gliomas: data from the Glioma Outcomes Project. J Neurosurg 2003; 99: 467-73.LawsERParneyIFHuangWAndersonFMorrisAMAsherAet alSurvival following surgery and prognostic factors for recently diagnosed malignant gliomas: data from the Glioma Outcomes ProjectJ Neurosurg2003994677310.3171/jns.2003.99.3.0467Search in Google Scholar
Lamborn KR, Chang SM, Prados MD. Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 2004; 6: 227-35.LambornKRChangSMPradosMDPrognostic factors for survival of patients with glioblastoma: recursive partitioning analysisNeuro Oncol200462273510.1215/S1152851703000620Search in Google Scholar
Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, et al. Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 2698122981/CE.3. Lancet Oncol 2008; 9: 29-38.GorliaTvan den BentMJHegiMEMirimanoffROWellerMCairncrossJGet alNomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 2698122981/CE.3Lancet Oncol20089293810.1016/S1470-2045(07)70384-4Search in Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.StuppRMasonWPvan den BentMJWellerMFisherBTaphoornMJBet alRadiotherapy plus concomitant and adjuvant temozolomide for glioblastomaN Engl J Med20053529879610.1056/NEJMoa04333015758009Search in Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.HegiMEDiserensACGorliaTHamouMFde TriboletNWellerMet alMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med2005352997100310.1056/NEJMoa04333115758010Search in Google Scholar
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 Mutations in Gliomas. N Engl J Med 2009; 360: 765-73.YanHParsonsDWJinGMcLendonRRasheedBAYuanWet alIDH1 and IDH2 Mutations in GliomasN Engl J Med20093607657310.1056/NEJMoa0808710282038319228619Search in Google Scholar
Boisselier B, Marie Y, Labussière M, Ciccarino P, Desestret V, Wang X, et al. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations. Hum Mutat 2010; 31: 1360-5.BoisselierBMarieYLabussièreMCiccarinoPDesestretVWangXet alCOLD PCR HRM: a highly sensitive detection method for IDH1 mutationsHum Mutat2010311360510.1002/humu.21365Search in Google Scholar
Labussiere M, Sanson M, Idbaih A, Delattre JY. IDH1 gene mutations: a new paradigm in glioma prognosis and therapy? Oncologist 2010; 15: 196-9.LabussiereMSansonMIdbaihADelattreJYIDH1 gene mutations: a new paradigm in glioma prognosis and therapy?Oncologist201015196910.1634/theoncologist.2009-0218Search in Google Scholar
Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, et al. Patterns of care for adults with newly diagnosed malignant gliomas. JAMA 2005; 293: 557-64.ChangSMParneyIFHuangWAndersonFAJrAsherALBernsteinMet alPatterns of care for adults with newly diagnosed malignant gliomasJAMA20052935576410.1001/jama.293.5.557Search in Google Scholar
Wen Py, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.WenPyKesariSMalignant gliomas in adultsN Engl J Med200835949250710.1056/NEJMra0708126Search in Google Scholar
Wheen LC, Anderson NE, Baker PC, Singh VK, Synek BJ. Leptomeningeal infiltration as the presenting manifestation of a malignant gliomas. J Clin Neurosci 2006; 13: 298-301.WheenLCAndersonNEBakerPCSinghVKSynekBJLeptomeningeal infiltration as the presenting manifestation of a malignant gliomasJ Clin Neurosci20061329830110.1016/j.jocn.2005.01.010Search in Google Scholar
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013; 310: 1842-50.OmuroADeAngelisLMGlioblastoma and other malignant gliomas: a clinical reviewJAMA201331018425010.1001/jama.2013.280319Search in Google Scholar
Cha S. Update on brain tumour imaging: from anatomy to phisiology. AJNR Am J Neuroradiol 2006; 27: 475-87.ChaSUpdate on brain tumour imaging: from anatomy to phisiologyAJNR Am J Neuroradiol20062747587Search in Google Scholar
Paleologogs TS, Dorward NL, Wadley JP, Thomas DG. Clinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive cases. Neurosurgery 2001; 49: 835-7.PaleologogsTSDorwardNLWadleyJPThomasDGClinical validation of true frameless stereotactic biopsy: analysis of the first 125 consecutive casesNeurosurgery2001498357Search in Google Scholar
Bernays RL, Kollias SS, Khan N, Brandner S, Meier S, Yonekawa Y. Histological yield, complications and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imageing. J Neurosurg 2002; 97: 354-62.BernaysRLKolliasSSKhanNBrandnerSMeierSYonekawaYHistological yield complications and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imageingJ Neurosurg2002973546210.3171/jns.2002.97.2.0354Search in Google Scholar
Maza S, Buchert R, Brenner W, Munz DL, Thiel E, Korfel A, et al. Brain and whole-body FDG-PET in diagnosis, treatment monitoring and long-term follow-up of primary CNS lymphoma. Radiol Oncol 2013; 47: 103-10.MazaSBuchertRBrennerWMunzDLThielEKorfelAet alBrain and whole-body FDG-PET in diagnosis treatment monitoring and long-term follow-up of primary CNS lymphomaRadiol Oncol2013471031010.2478/raon-2013-0016Search in Google Scholar
Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, et al. Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 2004; 45: 1293-8.PirotteBGoldmanSMassagerNDavidPWiklerDVandesteeneAet alComparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomasJ Nucl Med20044512938Search in Google Scholar
Stupp R, Hegi EM, Mason PW, van den Bent MJ, Taphoorn JBM, Janzer CR, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-66.StuppRHegiEMMasonPWvan den BentMJTaphoornJBMJanzerCRet alEffects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialLancet Oncol2009104596610.1016/S1470-2045(09)70025-7Search in Google Scholar
Stewart LA. Chemotherapy in adult high-grade gliomas: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-8.StewartLAChemotherapy in adult high-grade gliomas: a systematic review and meta-analysis of individual patient data from 12 randomised trialsLancet20023591011810.1016/S0140-6736(02)08091-1Search in Google Scholar
Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Warnke PC, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomas. Neuro Oncol 2003; 5: 79-88.WestphalMHiltDCBorteyEDelavaultPOlivaresRWarnkePCet alA phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant gliomasNeuro Oncol20035798810.1093/neuonc/5.2.79192067212672279Search in Google Scholar
Westphal M, Ram Z, Riddle V, Hilt D, Bortey E. Gliadel wafer in initial surgery for malignant gliomas: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 2006; 148: 269-75.WestphalMRamZRiddleVHiltDBorteyEGliadel wafer in initial surgery for malignant gliomas: long-term follow-up of a multicenter controlled trialActa Neurochir (Wien)20061482697510.1007/s00701-005-0707-z16482400Search in Google Scholar
Gilbert MR, Dignam J, Won M, Blumenthal DT, Vogelbaum MA, Aldape KD, et al. RTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). [Abstract]. 2013 ASCO Annual Meeting. J Clin Oncol 2013; 31(18 Suppl): Abstract No. 1.GilbertMRDignamJWonMBlumenthalDTVogelbaumMAAldapeKDet alRTOG 0825: phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM). [Abstract]. 2013 ASCO Annual MeetingJ Clin Oncol20133118 SupplAbstract No 110.1200/jco.2013.31.18_suppl.1Search in Google Scholar
Henriksson R, Bottomley A, Mason W, Saran F, Wick W, Nishikawa R, et al. Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). [Abstract]. 2013 ASCO Annual Meeting. J Clin Oncol 2013; 31(18 Suppl): Abstract No. 2005.HenrikssonRBottomleyAMasonWSaranFWickWNishikawaRet alProgression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma (GBM). [Abstract]. 2013 ASCO Annual MeetingJ Clin Oncol20133118 SupplAbstract No 200510.1200/jco.2013.31.15_suppl.2005Search in Google Scholar
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, et al. Central nervous system cancers. J Natl Compr Canc Netw 2011; 9: 352-400.BremSSBiermanPJBremHButowskiNChamberlainMCChioccaEAet alCentral nervous system cancersJ Natl Compr Canc Netw2011935240010.6004/jnccn.2011.003621464144Search in Google Scholar
van den Bent MJ. Anaplastic oligodendroglioma and oligoastrocytoma. Neurol Clin 2007; 25: 1089-109.van den BentMJAnaplastic oligodendroglioma and oligoastrocytomaNeurol Clin200725108910910.1016/j.ncl.2007.07.01317964027Search in Google Scholar
Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852-61.JenkinsRBBlairHBallmanKVGianniniCArusellRMLawMet alA t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendrogliomaCancer Res20066698526110.1158/0008-5472.CAN-06-179617047046Search in Google Scholar
Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 2006; 24: 2707-14.Intergroup Radiation Therapy Oncology Group Trial 9402CairncrossGBerkeyBShawEJenkinsRScheithauerBet alPhase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402J Clin Oncol20062427071410.1200/JCO.2005.04.341416782910Search in Google Scholar
van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 2006; 24: 2715-22.van den BentMJCarpentierAFBrandesAASansonMTaphoornMJBernsenHJet alAdjuvant procarbazine lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trialJ Clin Oncol20062427152210.1200/JCO.2005.04.607816782911Search in Google Scholar
Sathorsumetee S, Rich JN, Reardon DA. Diagnosis and treatment of high grade astrocytoma. Neurol Clin 2007; 25: 1111-39.SathorsumeteeSRichJNReardonDADiagnosis and treatment of high grade astrocytomaNeurol Clin20072511113910.1016/j.ncl.2007.07.00417964028Search in Google Scholar
Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-710.FurnariFBFentonTBachooRMMukasaAStommelJMSteghAet alMalignant astrocytic glioma: genetics, biology, and paths to treatmentGenes Dev200721268371010.1101/gad.159670717974913Search in Google Scholar
Chi AS, Wen PY. Inhibiting kinases in malignant gliomas. Expert Opin Ther Targets 2007; 11: 473-96.ChiASWenPYInhibiting kinases in malignant gliomasExpert Opin Ther Targets2007114739610.1517/14728222.11.4.47317373878Search in Google Scholar
Sathorsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant gliomas. Cancer 2007; 110: 13-24.SathorsumeteeSReardonDADesjardinsAQuinnJAVredenburghJJRichJNMolecularly targeted therapy for malignant gliomasCancer2007110132410.1002/cncr.2274117520692Search in Google Scholar
Fiegler W, Langer M, Scheer M, Kazner E. [Reversible computed tomographic changes following brain tumour irradiation induced by the “early-delayed reaction” after radiation]. [German]. Radiologe 1986; 26: 206-9.FieglerWLangerMScheerMKaznerE[Reversible computed tomographic changes following brain tumour irradiation induced by the “early-delayed reaction” after radiation]. [German]Radiologe1986262069Search in Google Scholar
Watne K, Hager B, Heier M, Hirschberg H. Reversible oedema and necrosis after irradiation of the brain. Diagnostic procedures and clinical manifestations. Acta Oncol 1990; 29: 891-5.WatneKHagerBHeierMHirschbergHReversible oedema and necrosis after irradiation of the brain Diagnostic procedures and clinical manifestationsActa Oncol199029891510.3109/028418690090963852261204Search in Google Scholar
Griebel M, Friedman HS, Halperin EC, Wiener MD, Marks L, Oakes WJ, et al. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem gliomas. Med Pediatr Oncol 1991; 19: 182-6.GriebelMFriedmanHSHalperinECWienerMDMarksLOakesWJet alReversible neurotoxicity following hyperfractionated radiation therapy of brain stem gliomasMed Pediatr Oncol199119182610.1002/mpo.29501903071902547Search in Google Scholar
de Wit MC, de Bruin HG, Eijkenboom W, Sillevis Smitt PA, van den Bent MJ. Immediate post-radiotherapy changes in malignant gliomas can mimic tumour progression. Neurology 2004; 63: 535-7.de WitMCde BruinHGEijkenboomWSillevis SmittPAvan den BentMJImmediate post-radiotherapy changes in malignant gliomas can mimic tumour progressionNeurology200463535710.1212/01.WNL.0000133398.11870.9ASearch in Google Scholar
Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Smitt PA, et al. The incidence of pseudoprogression in a cohort of malignant gliomas patients treated with chemo-radiation with temozolomide. [Abstract]. Proc Am Soc Clin Oncol 2007; 25: Abstract No. 2009.TaalWBrandsmaDde BruinHGBrombergJESwaak-KragtenATSmittPAet alThe incidence of pseudoprogression in a cohort of malignant gliomas patients treated with chemo-radiation with temozolomide [Abstract]Proc Am Soc Clin Oncol200725Abstract No 200910.1200/jco.2007.25.18_suppl.2009Search in Google Scholar
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192-7.BrandesAAFranceschiETosoniABlattVPessionATalliniGet alMGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patientsJ Clin Oncol2008262192710.1200/JCO.2007.14.816318445844Search in Google Scholar
Kos N, Kos B, Benedicic M. Early medical rehabilitation after neurosurgical treatment of malignant brain tumours in Slovenia. Radiol Oncol 2015; 49: in press.KosNKosBBenedicicMEarly medical rehabilitation after neurosurgical treatment of malignant brain tumours in SloveniaRadiol Oncol201549in press10.1515/raon-2015-0004485296627247545Search in Google Scholar
Keles GE, Lamborn KR, Chang SM, Prados MD, Berger MS. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg 2004; 100: 41-6.KelesGELambornKRChangSMPradosMDBergerMSVolume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapyJ Neurosurg200410041610.3171/jns.2004.100.1.004114743910Search in Google Scholar
Tsao MN, Mehta MP, Whelan TJ, Morris DE, Hayman JA, Flickinger JC, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant gliomas. Int J Radiat Oncol Biol Phys 2005; 63: 47-55.TsaoMNMehtaMPWhelanTJMorrisDEHaymanJAFlickingerJCet alThe American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for malignant gliomasInt J Radiat Oncol Biol Phys200563475510.1016/j.ijrobp.2005.05.02416111571Search in Google Scholar
Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005; 23: 8863-9.CombsSEThilmannCEdlerLDebusJSchulz-ErtnerD.Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institutionJ Clin Oncol2005238863910.1200/JCO.2005.03.415716314646Search in Google Scholar
Kong DS, Lee JI, Park K, Kim JH, Lim DH, Nam DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer 2008; 112: 2046-51.KongDSLeeJIParkKKimJHLimDHNamDHEfficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomasCancer200811220465110.1002/cncr.2340218338759Search in Google Scholar
Prados MD, Yung WKA, Fine HA, Greenberg HS, Junck L, Chang SM, et al. Phase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium study. Neuro Oncol 2004; 6: 33-7.PradosMDYungWKAFineHAGreenbergHSJunckLChangSMet alPhase 2 study of BCNU and temozolomide for recurrent glioblastoma multiforme: North American Brain Tumor Consortium studyNeuro Oncol2004633710.1215/S1152851703000309187197514769138Search in Google Scholar
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, et al. Outcomes and prognostic factors in recurrent gliomas patients enrolled onto phase II clinical trials. J Clin Oncol 1999; 17: 2572-8.WongETHessKRGleasonMJJaeckleKAKyritsisAPPradosMDet alOutcomes and prognostic factors in recurrent gliomas patients enrolled onto phase II clinical trialsJ Clin Oncol1999172572810.1200/JCO.1999.17.8.257210561324Search in Google Scholar
Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-93.YungWKAlbrightREOlsonJFredericksRFinkKPradosMDet alA phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer2000835889310.1054/bjoc.2000.1316236350610944597Search in Google Scholar
Brock CS, Newlands ES, Wedge SR, Bower M, Evans H, Colquhoun I, et al. Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Res 1998; 58: 4363-7.BrockCSNewlandsESWedgeSRBowerMEvansHColquhounIet alPhase I trial of temozolomide using an extended continuous oral scheduleCancer Res19985843637Search in Google Scholar
Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-11.TolcherAWGersonSLDenisLGeyerCHammondLAPatnaikAet alMarked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedulesBr J Cancer20038810041110.1038/sj.bjc.6600827237638412671695Search in Google Scholar
Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004; 62: 2113-5.WickWSteinbachJPKukerWMDichgansJBambergMWellerMOne week on/one week off: a novel active regimen of temozolomide for recurrent glioblastomaNeurology2004622113510.1212/01.WNL.0000127617.89363.84Search in Google Scholar
Su YB, Sohn S, Krown SE, Livingston PO, Wolchok JD, Quinn C, et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. J Clin Oncol 2004; 22: 610-6.SuYBSohnSKrownSELivingstonPOWolchokJDQuinnCet alSelective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implicationsJ Clin Oncol200422610610.1200/JCO.2004.07.06014726505Search in Google Scholar
Wick W, Weller M. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. J Clin Oncol 2005; 23: 4235-6; author reply 4236.WickWWellerMHow lymphotoxic is dose-intensified temozolomide? The glioblastoma experienceJ Clin Oncol20052342356author reply 423610.1200/JCO.2004.00.841715961774Search in Google Scholar
Brandes AA, Tosoni A, Amistà P, Nicolardi L, Grosso D, Berti F, et al. How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 2004; 63: 1281-4.BrandesAATosoniAAmistàPNicolardiLGrossoDBertiFet alHow effective is BCNU in recurrent glioblastoma in the modern era? A phase II trialNeurology2004631281410.1212/01.WNL.0000140495.33615.CASearch in Google Scholar
Schmidt F, Fischer J, Herrlinger U, Dietz K, Dichgans J, Weller M. PCV chemotherapy for recurrent glioblastoma. Neurology 2006; 66: 587-9.SchmidtFFischerJHerrlingerUDietzKDichgansJWellerMPCV chemotherapy for recurrent glioblastomaNeurology200666587910.1212/01.wnl.0000197792.73656.c216505319Search in Google Scholar
Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-5.KreislTNKimLMooreKDuicPRoyceCStroudIet alPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927740510.1200/JCO.2008.16.3055264508819114704Search in Google Scholar
Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-40.FriedmanHSPradosMDWenPYMikkelsenTSchiffDAbreyLEet alBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol20092747334010.1200/JCO.2008.19.872119720927Search in Google Scholar
Cloughesy T, Vredenburgh JJ, Day B, Das A, Friedman HS. Updated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study. [Abstract]. J Clin Oncol 2010; 28(15 Suppl): Abstract No. 3085.CloughesyTVredenburghJJDayBDasAFriedmanHSUpdated safety and survival of patients with relapsed glioblastoma treated with bevacizumab in the BRAIN study [Abstract]J Clin Oncol20102815 SupplAbstract No 308510.1200/jco.2010.28.15_suppl.2008Search in Google Scholar
NCCN clinical practical guidelines in oncology. Central nervous system cancer. Version 2.2013. Available from: http://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#site. Accessed on 7 August 2012.NCCN clinical practical guidelines in oncologyCentral nervous system cancer Version 2.2013Available fromhttp://www.nccn.org/professionals/ physician_gls/f_guidelines.asp#siteAccessed on 7 August 2012Search in Google Scholar
Stupp R, Tonn JC, Brada M, Pentheroudakis G. High grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): v190-3.StuppRTonnJCBradaMPentheroudakisGHigh grade malignant glioma: ESMO clinical practice guidelines for diagnosis treatment and follow-upAnn Oncol201021Suppl 5v190310.1093/annonc/mdq18720555079Search in Google Scholar
Mesti T, Ebert Moltara M, Boc M, Reberšek M, Ocvirk J. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience. Radiol Oncol 2014. Ahead of print. doi:10.2478/raon-2014-0021MestiTEbert MoltaraMBocMReberšekMOcvirkJBevacizumab and irinotecan in recurrent malignant glioma a single institution experienceRadiol Oncol2014Ahead of print10.2478/raon-2014-0021436261125810706Open DOISearch in Google Scholar
Wick W, Engel C, Combs SE, Nikkhah G, Steinbach J, Kortmann R, et al. NOA08 randomized phase III trial of 1 week on/1 week off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). [Abstract]. J Clin Oncol 2010; 28: 949s. Abstract No. LBA2001.WickWEngelCCombsSENikkhahGSteinbachJKortmannRet alNOA08 randomized phase III trial of 1 week on/1 week off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). [Abstract]J Clin Oncol201028949sAbstract No LBA200110.1200/jco.2010.28.18_suppl.lba2001Search in Google Scholar
Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007; 356: 1527-35.Keime-GuibertFChinotOTaillandierLCartalat-CarelSFrenayMKantorGet alRadiotherapy for glioblastoma in the elderlyN Engl J Med200735615273510.1056/NEJMoa06590117429084Search in Google Scholar
Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004; 22: 1583-8.RoaWBrasherPMBaumanGAnthesMBrueraEChanAet alAbbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trialJ Clin Oncol2004221583810.1200/JCO.2004.06.08215051755Search in Google Scholar
Glantz M, Chamberlain M, Liu Q, Litofsky NS, Recht LD. Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003; 97: 2262-6.GlantzMChamberlainMLiuQLitofskyNSRechtLDTemozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomasCancer2003972262610.1002/cncr.1132312712481Search in Google Scholar
Malmstrom A, Gronberg BH, Stupp R, Marosi C, Frappaz D, Schultz HP, et al. Glioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single agent chemotherapy (TMZ) for glioblastoma (GBM) in the elderly. [Abstract]. J Clin Oncol 2010; 28(18 Suppl): 949s. Abstract No. LBA2002MalmstromAGronbergBHStuppRMarosiCFrappazDSchultzHPet alGlioblastoma (GBM) in elderly patients: a randomized phase III trial comparing survival in patients treated with 6-week radiotherapy (RT) versus hypofractionated RT over 2 weeks versus temozolomide single agent chemotherapy (TMZ) for glioblastoma (GBM) in the elderly [Abstract]J Clin Oncol20102818 Suppl949sAbstract No LBA200210.1200/jco.2010.28.18_suppl.lba2002Search in Google Scholar
